| HOME >> BIOLOGY >> TECHNOLOGY |
1,030,205Fixed Assets - Net605,920
278,208Restricted Cash88,321
—Other Assets 120,890
100,419Total assets$
9,043,223
$
,408,832Liabilities and Stockholders' DeficitCurrent LiabilitiesAccounts payable$
,347
$
57,560Accrued expenses830,033
437,837Deferred revenue75,000
152,500Capital lease obligation, current portion
9,845
—Accrued interest payable—
24,018Convertible notes payable, current portion—
703,833Total current liabilities976,225
1,975,748Capital lease obligation, net current portion19,712
—Warrant Liabilities35,471,527
1,266,869Total liabilities$36,467,464
$
3,242,617Commitments and Contingencies Stockholders' DeficitCommon stock, $0.001 par value; 150,000,000
shares authorized, 43,772,483 and 22,445,254
issued and outstanding at September 30, 2012
and December 31, 2011, respectively46,969
22,445Additional paid-in capital13,208,039
4,835,326Deficit accumulated during the development stage(40,679,249)
(6,691,556)Total stockholders' deficit
(27,424,241)
(1,833,785)Total Liabilities and Stockholders' Deficit$
9,043,223
$
,408,832 Organovo Holdings, Inc.(A development stage company)Unaudited Condensed Consolidated Statements of OperationsThree Months EndedSeptember 30, 2012
Three Months EndedSeptember 30, 2011
Nine Months EndedSeptember 30, 2012
Nine Months EndedSeptember 30, 2011
Period fromApril 19, 2007(Inception)throughSeptember 30, 2012 RevenuesProduct$
8212;
$
8212;
$
8212;
$
,000
$
223,500Collaborations373,761
231,974
752,736
449,213<
'/>"/>
| SOURCE Organovo Holdings, Inc. Copyright©2012 PR Newswire. All rights reserved |